{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Elicio Therapeutics Hits New 52-Week High of $12.61
Elicio Therapeutics, Inc. achieved a new 52-week high, reflecting strong performance over the past year, significantly outpacing the S&P 500. With a market capitalization of USD 191 million, the company, despite being unprofitable, shows potential in the Pharmaceuticals & Biotechnology sector, emphasizing growth over immediate returns.
Is Elicio Therapeutics, Inc. overvalued or undervalued?
As of May 10, 2023, Elicio Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative financial metrics, including a Price to Book Value of 14.08 and an alarming Return on Equity of -508.10%, despite a year-to-date stock performance of 57.25%.
Is Elicio Therapeutics, Inc. technically bullish or bearish?
As of June 17, 2025, the market trend is bullish, supported by positive daily moving averages and a bullish weekly MACD, despite some mixed signals from the KST and Dow Theory indicating a mildly bullish trend.
What does Elicio Therapeutics, Inc. do?
Elicio Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $11 million and a market cap of $127.29 million. Key financial metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -508.10%.
How big is Elicio Therapeutics, Inc.?
As of Jun 18, Elicio Therapeutics, Inc. has a market capitalization of 127.29 million, with recent net sales of 0.00 million and a net profit of -51.28 million for the last four quarters. As of December 2024, the company reported shareholder's funds of -11.31 million and total assets of 28.18 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
